<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon syndrome</z:e> is a non-inflammatory, non-atherosclerotic disease involving small and medium-sized arteries of the brain and of the skin </plain></SENT>
<SENT sid="1" pm="."><plain>The arteriographic examination is often negative despite progressive impairment of the neurological status </plain></SENT>
<SENT sid="2" pm="."><plain>In 3 patients with <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon syndrome</z:e> cerebral perfusion was assessed with single <z:chebi fb="23" ids="30212">photon</z:chebi> emission computerized tomography (SPECT) and <z:chebi fb="0" ids="33371">technetium99</z:chebi> m-hexamethylpropylenamineoxime (Tc99 HM <z:chebi fb="1" ids="53240">PAO</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>A correlation between clinical and SPECT finding was found, with significant focal reduction of regional cerebral blood flow (rCBF) in the two more severely affected patients </plain></SENT>
</text></document>